Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218956 | 0.78 | MAOA (0.57) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL5217094 | 0.78 | MAOA (0.46) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL8078642 | 0.77 | MAPT (0.57) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL1615170 | 0.76 | MAOB (0.51) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL2126343 | 0.76 | MAOA (0.51) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL5216775 | 0.74 | MAOA (0.40) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL5220041 | 0.73 | MAOA (0.45) | MAPTRAB9ACYP1A2CYP3A4MAOA | |
| SCHEMBL2762900 | 0.73 | MAOA (0.51) | MAPTRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL5222634 | 0.72 | MAOA (0.41) | MAPTRAB9ACYP1A2CYP3A4MAOA | |
| SCHEMBL1614833 | 0.72 | MAPT (0.45) | MAPTRAB9ANPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1723206-B | High specificity anticancer pharmacological drug system, drug synthesis and drug formulation development method | WALKER CANCER RES INST INC | 2010-05-26 | — | — | CN | claimed |
| CN-1723206-A | High specificity anticancer pharmacological drug system, drug synthesis and drug formulation development method | WALKER CANCER RES INST INC (US) | 2006-01-18 | — | — | CN | claimed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | claimed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | claimed |
| US-20040192578-A1 | High specificity anticancer drug design process | WALKER EVAN HARRIS (US) | 2004-09-30 | — | — | US | disclosed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | disclosed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192578-A1 | High specificity anticancer drug design process | MCL1, ABCG2, TP53 | MAPT 2527/4885RAB9A 2148/4885NPC1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.